VR Logo

Candel Therapeutics Inc. (CADL) download report


Healthcare | Biotechnology & Pharma Research

Candel Therapeutics Inc. (CADL) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.

IPO Date: 27-Jul-2021

Pres, CEO & Director: Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.

Founder & Director: Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D.

Listing: NASDAQ: CADL

Country: United States

Headquarters: Needham, MA

Website: https://www.candeltx.com

Key Facts

Market cap: $92.11 Mln

Revenue (TTM): $0.12 Mln

Earnings (TTM): $-32.52 Mln

Cash: $94.32 Mln

Total Debt: $22.79 Mln

Insider's Holding: 33.48%

Liquidity: Low

52 Week range: $3.00 - 14.78

Shares outstanding: 28,693,200

Stock Performance

Time Period Candel Therapeutics (CADL) S&P BSE Sensex S&P Small-Cap 600
YTD-58.95-9.18-18.78
1 month-24.47-4.78-8.00
3 months-36.94-9.66-13.65
1 Year--0.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022